Username Password
S&P 500: 1,988.87
Change: +0.06%

EXELIXIS INC. (EXEL)

Overview
Price 6.05
Price Change Today -$0.04 (-0.66%)
P&P rating Rating: 3
Open Price $6.05
Previous Close $6.09
Daily Range $5.96 - $6.17
52-Week Range $1.26 - $6.81
Volume 4
chart
Top Buy Analysis
BUY: EXEL Rating: 3
Company: EXELIXIS INC.
Points: 6.33
Start Price: $4.77
Start Date: 05/23/2013 8:49 AM
BriansLongshots
BriansLongshots
P&P Score: 99.45
Recs:
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Top Sell Analysis
SELL: EXEL Rating: 3
Company: EXELIXIS INC.
Points: 91.71
Start Price: $9.35
Start Date: 06/19/2011 9:24 AM
Hqdepot
Hqdepot
P&P Score: 51.59
Recs:
I bought at 2.99 and took a 100+ gain at 6.45. Then I watched it ratchet up to 12. Makes you want to put on a blindfold and slide quarters into a slot machine. Anyway. It looks tenuous here and the news concerning side effects of their big Phase 3 drug is not promising. I see some downside to the 6.5 area here.

Comments: 0 | Comment

Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

28 Buy
1 Sell
 
Blog Posts
User User Score Date Title Comments Last Comment
zantriocom
0.00 03/10/10 Zantrio.com Free Daily Stock Picks 3-10-2010 0
zantriocom
0.00 11/09/09 Zantrio.com Free Daily Stock Picks 11-9-09 0
Zacks_Analysts
0.00 01/18/13 Pipeline Advances at Exelixis - Analyst Blog 0
Zacks_Analysts
0.00 01/18/13 Pipeline Advances at Exelixis - Analyst Blog 0
Zacks_Analysts
0.00 12/20/10 Sanofi Expands Oncology Pipeline - Analyst Blog 0
Zacks_Analysts
0.00 07/26/10 Sanofi Launches Cancer Treatment - Analyst Blog 0
Zacks_Analysts
0.00 06/30/10 Sanofi to Acquire TargaGen - Analyst Blog 0
Zacks_Analysts
0.00 06/22/10 BMY Terminates EXEL Partnership - Analyst Blog 0
Zacks_Analysts
0.00 06/18/10 FDA Approves Sanofi Drug - Analyst Blog 0
Zacks_Analysts
0.00 06/07/10 Sanofi Expands Oncology Pipeline - Analyst Blog 0
Pages: [ 1 ]  2  >>
Commentary
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: +6.33
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: -0.70
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: -0.88
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: +6.33
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: -0.70
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
BUY: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $4.77
Points: -0.88
Created: 05/23/2013
Phase 3 trials nearing completion. Great preliminary results against various cancers.

Comments: 0 | Comment

Recs:
 
SELL: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $9.35
Points: +91.71
Created: 06/19/2011
I bought at 2.99 and took a 100+ gain at 6.45. Then I watched it ratchet up to 12. Makes you want to put on a blindfold and slide quarters into a slot machine. Anyway. It looks tenuous here and the news concerning side effects of their big Phase 3 drug is not promising. I see some downside to the 6.5 area here.

Comments: 0 | Comment

Recs:
 
SELL: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $9.35
Points: +100.85
Created: 06/19/2011
I bought at 2.99 and took a 100+ gain at 6.45. Then I watched it ratchet up to 12. Makes you want to put on a blindfold and slide quarters into a slot machine. Anyway. It looks tenuous here and the news concerning side effects of their big Phase 3 drug is not promising. I see some downside to the 6.5 area here.

Comments: 0 | Comment

Recs:
 
SELL: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $9.35
Points: +101.08
Created: 06/19/2011
I bought at 2.99 and took a 100+ gain at 6.45. Then I watched it ratchet up to 12. Makes you want to put on a blindfold and slide quarters into a slot machine. Anyway. It looks tenuous here and the news concerning side effects of their big Phase 3 drug is not promising. I see some downside to the 6.5 area here.

Comments: 0 | Comment

Recs:
 
SELL: EXELIXIS INC. (EXEL) Rating: 3
Start Price: $9.35
Points: +91.71
Created: 06/19/2011
I bought at 2.99 and took a 100+ gain at 6.45. Then I watched it ratchet up to 12. Makes you want to put on a blindfold and slide quarters into a slot machine. Anyway. It looks tenuous here and the news concerning side effects of their big Phase 3 drug is not promising. I see some downside to the 6.5 area here.

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2   3  >>
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +20.50% +6.33 view
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +27.54% -0.70 view
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +27.72% -0.88 view
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +20.50% +6.33 view
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +27.54% -0.70 view
BriansLongshots 99.45 BUY Three Plus Years 05/23/2013 $4.77 $6.05
(-0.66%)
+26.83% +27.72% -0.88 view
rtezanos 1.24 BUY Week or Less 10/19/2011 $5.57 $6.05
(-0.66%)
+8.62% +64.39% -55.77 view
rtezanos 1.24 BUY Week or Less 10/19/2011 $5.57 $6.05
(-0.66%)
+8.62% +73.98% -65.37 view
rtezanos 1.24 BUY Week or Less 10/19/2011 $5.57 $6.05
(-0.66%)
+8.62% +74.23% -65.61 view
rtezanos 1.24 BUY Week or Less 10/19/2011 $5.57 $6.05
(-0.66%)
+8.62% +64.39% -55.77 view
Pages: [ 1 ]  2   3  >>
Sponsored Links